Show Indication & Important Safety InformationIndication Statement:
TOVIAZ® (fesoterodine fumarate) is indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.
Toviaz® (fesoterodine fumarate)
Featured Information
TOVIAZ® (fesoterodine fumarate) head-to-head study:From the first placebo-controlled, head-to-head trials between two antimuscarinics for the treatment of overactive bladder symptoms.1,2
|
TOVIAZ Indication and Important Safety Information
Please scroll to see the Indication below.
IMPORTANT SAFETY INFORMATION
TOVIAZ is contraindicated in patients with urinary retention, gastric retention, or uncontrolled narrow-angle glaucoma, and in patients with known hypersensitivity to the drug or its ingredients.
TOVIAZ tablets should be used with caution in patients with clinically significant bladder outlet obstruction, decreased gastrointestinal motility, controlled narrow-angle glaucoma, or myasthenia gravis. TOVIAZ is not recommended for use in patients with severe hepatic impairment.
The recommended starting dose of TOVIAZ is 4 mg once daily. Based upon individual response and tolerability, the dose may be increased to 8 mg once daily. Doses greater than 4 mg are not recommended in patients with severe renal insufficiency or in patients taking a potent CYP3A4 inhibitor; in patients taking a weak or moderate CYP3A4 inhibitor, careful assessment at 4 mg is advised prior to increasing to 8 mg.
The most frequently reported adverse events (≥4%) for TOVIAZ were: dry mouth (placebo, 7%; TOVIAZ 4 mg, 19%; TOVIAZ 8 mg, 35%) and constipation (placebo, 2%; TOVIAZ 4 mg, 4%; TOVIAZ 8 mg, 6%).
Download the Full U.S. Prescribing and Patient Information.
Indication Statement:
TOVIAZ® (fesoterodine fumarate) is indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.
Please see full prescribing information.